Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo

Oncology Research

Volumn 20, Issue 2-3, 2012, Pages 49-59

  Li, Wei ^a   Zhai, Lingyun ^a   Tang, Yunxian ^a   Cai, Jiahui ^a   Liu, Meilin ^a   Zhang, Jun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Celecoxib; Cell proliferation; Cyclin D1; Ovarian carcinoma; SC 560; Taxol

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CELECOXIB; CYCLIN D1; PACLITAXEL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

EID: 84869039414     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504012X13473664562466     Document Type: Article

References (44)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60:277-300; 2010.
2. Pignata, S.; Scambia, G.; Ferrandina, G.; Savarese, A.; Sorio, R.; Breda, E.; Gebbia, V.; Musso, P.; Frigerio, L.; Del Medico, P.; Lombardi, A. V.; Febbraro, A.; Scollo, P.; Ferro, A.; Tamberi, S.; Brandes, A.; Ravaioli, A.; Valerio, M. R.; Aitini, E.; Natale, D.; Scaltriti, L.; Greggi, S.; Pisano, C.; Lorusso, D.; Salutari, V.; Legge, F.; Di Maio, M.; Morabito, A.; Gallo, C.; Perrone, F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 Randomized Phase III Trial. J. Clin. Oncol. 29:3628-3635; 2011.
3. Wang, Y.; Qu, Y.; Niu, X. L.; Sun, W. J.; Zhang, X. L.; Li, L. Z. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 56:365-375; 2011.
4. Harris, R. E.; Beebe-Donk, J.; Doss, H.; Burr Doss, D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade. Oncol. Rep. 13:559-583; 2005.
5. Athanassiadou, P.; Grapsa, D.; Athanassiades, P.; Gonidi, M.; Athanassiadou, A. M.; Tsipis, A.; Patsouris, E. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol. Res. Pract. 204:241-249; 2008.
6. Lau, M. T.; Wong, A. S.; Leung, P. C. Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E2 production in human ovarian cancer cells. Endocrinology 151: 2985-2993; 2010.
7. Ali-Fehmi, R.; Semaan, A.; Sethi, S.; Arabi, H.; Bandyo-padhyay, S.; Hussein, Y. R.; Diamond, M. P.; Saed, G.; Morris, R. T.; Munkarah, A. R. Molecular typing of epithelial ovarian carcinomas using inflammatory markers. Cancer 117:301-309; 2011.
8. Gu, P.; Su, Y.; Guo, S.; Teng, L.; Xu, Y.; Qi, J.; Gong, H.; Cai, Y. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Invest. 26:822-829; 2008.
9. Mutter, R.; Lu, B.; Carbone, D. P.; Csiki, I.; Moretti, L.; Johnson, D. H.; Morrow, J. D.; Sandler, A. B.; Shyr, Y.; Ye, F.; Choy, H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin. Cancer Res. 15:2158-2165; 2009.
10. Altorki, N. K.; Christos, P.; Port, J. L.; Lee, P. C.; Mirza, F.; Spinelli, C.; Keresztes, R.; Beneck, D.; Paul, S.; Stiles, B. M.; Zhang, Y.; Schrump, D. S. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J. Thorac. Oncol. 6:1121-1127; 2011.
11. Bhatt, R. S.; Merchan, J.; Parker, R.; Wu, H. K.; Zhang, L.; Seery, V.; Heymach, J. V.; Atkins, M. B.; McDermott, D.; Sukhatme, V. P. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116:1751-1756; 2010.
12. Saba, N. F.; Choi, M.; Muller, S.; Shin, H. J.; Tighiouart, M.; Papadimitrakopoulou, V. A.; El-Naggar, A. K.; Khuri, F. R.; Chen, Z. G.; Shin, D. M. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev. Res. 2:823-829; 2009.
13. Eichele, K.; Ramer, R.; Hinz, B.; Eichele, K.; Ramer, R.; Hinz, B. Decisive role of cyclooxygenase-2 and lipocalin- type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene 27:3032-3044; 2008.
14. Vane, J. R.; Bakhle, Y. S.; Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:97-120; 1998.
15. Uddin, S.; Ahmed, M.; Hussain, A.; Assad, L.; Al-Dayel, F.; Bavi, P.; Al-Kuraya, K. S.; Munkarah, A. Cyclooxygenase-2 inhibition inhibits PI3-K/AKT kinase activity in epithelial ovarian cancer. Int. J. Cancer 126:382-394; 2010.
16. Athanassiadou, P.; Grapsa, D.; Athanassiades, P.; Gonidi, M.; Athanassiadou, A. M.; Tsipis, A.; Patsouris, E. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol. Res. Pract. 204:241-249; 2008.
17. Ferrandina, G.; Ranelletti, F. O.; Martinelli, E.; Paglia, A.; Zannoni, G. F.; Scambia, G. Cyclooxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/ paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer 6:182; 2006.
18. Li, W.; Zhang, H. H.; Xu, R. J.; Zhuo, G. C.; Hu, Y. Q.; Li, J. Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo. Med. Oncol. 25:172-177; 2008.
19. Bijman, M. N.; Hermelink, C. A.; van Berkel, M. P.; Laan, A. C.; Janmaat, M. L.; Peters, G. J.; Boven, E. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem. Pharmacol. 75:427-437; 2008.
20. Li, W.; Xu, R. J.; Lin, Z. Y.; Zhuo, G. C.; Zhang, H. H. Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor. Med. Oncol. 26:170-177; 2009.
21. Li, W.; Wang, J.; Jiang, H. R.; Xu, X. L.; Zhang, J.; Liu, M. L.; Zhai, L. Y. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int. J. Mol. Sci. 12:668-681; 2011.
22. Williams, C. S.; Watson, A. J.; Sheng, H.; Helou, R.; Shao, J.; DuBois, R. N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res. 60: 6045-6051; 2000.
23. Gerdes, J.; Lemke, H.; Baisch, H.; Wacker, H. H.; Schwab, U.; Stein, H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1710-1715; 1984.
24. Weidner, N.; Folkman, J.; Pozza, F.; Bevilacqua, P.; Allred, E. N.; Moore, D. H.; Meli, S.; Gasparini, G. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84:1875-1887; 1992.
25. Del Vecchio, M. T.; Leoncini, L.; Buerki, K.; Kraft, R.; Megha, T.; Barbini, P.; Tosi, P.; Cottier, H. Diffuse controcytic and/or centroblastic malignant non-Hodgkins lymphomas: Comparison of mitotic and pyknotic (apoptotic) indices. Int. J. Cancer. 47:38-43; 1991.
26. Kumar, S.; Mahdi, H.; Bryant, C.; Shah, J. P.; Garg, G.; Munkarah, A. Clinical trials and progress with paclitaxel in ovarian cancer. Int. J. Womens Health 2:411-427; 2010.
27. Hida, T.; Kozaki, K.; Muramatsu, H.; Masuda, A.; Shimizu, S.; Mitsudomi, T.; Sugiura, T.; Ogawa, M.; Takahashi, T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6:2006-2011; 2000.
28. Merchan, J. R.; Jayaram, D. R.; Supko, J. G.; He, X.; Bubley, G. J.; Sukhatme, V. P. Increased endothelial uptake of paclitaxel as a potential mechanism for its anti-angiogenic effects: Potentiation by Cox-2 inhibition. Int. J. Cancer 113:490-498; 2005.
29. Andrews, P.; Zhao, X.; Allen, J.; Li, F.; Chang, M. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother. Pharmacol. 61:203-214; 2008.
30. Li, W.; Jiang, H. R.; Xu, X. L.; Wang, J.; Zhang, J.; Liu, M. L.; Zhai, L. Y. Cyclin d1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo. Int. J. Mol. Sci. 11:3999-4013; 2010.
31. Song, Y. C.; Kim, S. H.; Juhnn, Y. S.; Song, Y. S. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells. Ann. NY Acad. Sci. 1095: 26-34; 2007.
32. Daikoku, T.; Tranguch, S.; Chakrabarty, A.; Wang, D.; Khabele, D.; Orsulic, S.; Morrow, J. D.; Dubois, R. N.; Dey, S. K. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res. 67:5285-5292; 2007.
33. Kitamura, T.; Itoh, M.; Noda, T.; Matsuura, M.; Wakabayashi, K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knock-out mice. Int. J. Cancer 109:576-580; 2004.
34. Kirtikara, K.; Morham, S. G.; Raghow, R.; Laulederkind, S. J.; Kanekura, T.; Goorha, S.; Ballou, L. R. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J. Exp. Med. 187:517-523; 1998.
35. Pyrko, P.; Kardosh, A.; Liu, Y. T.; Soriano, N.; Xiong, W.; Chow, R. H.; Uddin, J.; Petasis, N. A.; Mircheff, A. K.; Farley, R. A.; Louie, S. G.; Chen, T. C.; Schönthal, A. H. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2, 5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol. Cancer Ther. 6:1262-1275; 2007.
36. Schönthal, A. H.: Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: Implications for glioma therapy. Neurosurg. Focus 20:E21; 2006.
37. Aune, G.; Stunes, A. K.; Tingulstad, S.; Salvesen, O.; Syversen, U.; Torp, S. H. The proliferation markers Ki-67/MIB-1, phospho histone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int. J. Clin. Exp. Pathol. 4:444-453; 2011.
38. Vital-Reyes, V.; Rodríguez-Burford, C.; Chhieng, D. C.; Oelschlager, D. K.; Reyes-Fuentes, A.; Barnes, M.; Grizzle, W. E. Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch. Med. Res. 37:689-695; 2006.
39. Worsley, S. D.; Ponder, B. A.; Davies, B. R. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol. Oncol. 64:189-195; 1997.
40. Masamha, C. P.; Benbrook, D. M. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 69:6565-572; 2009.
41. Gee, J. R.; Burmeister, C. B.; Havighurst, T. C.; Kim, K. Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer. Anticancer Res. 29: 3769-3775; 2009.
42. Lee, E.; Choi, M. K.; Han, I. O.; Lim, S. J. Role of p21CIP1 as a determinant of SC-560 response in human HCT116 colon carcinoma cells. Exp. Mol. Med. 38:325-331; 2006.
43. Hazelton, D. A.; Hamilton, T. C. Vascular endothelial growth factor on ovarian cancer. Curr. Oncol. Rep. 1:59-63; 1999.
44. Kim, Y. Y.; Lee, E. J.; Kim, Y. K.; Kim, S. M.; Park, J. Y.; Myoung, H.; Kim, M. J. Anti-cancer effects of celecoxib in head and neck carcinoma. Mol. Cells 29:185-194; 2010.